Copy to clipboard 
Ember Therapeutics entered into a letter of intent to divest its OP-1 bone morphogenetic protein (BMP-7) product family to Viscogliosi Brothers, LLC. The transaction is slated to close in late 3Q18 or 4Q18.
The OP-1 portfolio includes OP-1 Implant, OP-1 Putty, Opgenra and Osigraft for use in bone applications.
BMPs are members of the TGF-beta superfamily and guide mesenchymal stem cells to differentiate into osteoblasts to form bone in targeted tissues. Although 20 different recombinant human BMPs (rhBMPs) have been discovered, only rhBMP-2 is FDA approved and available for use in human spine surgery. BMP-7, marketed as OP-1, has potential use in treatment of osteoarthritis and other non-orthopaedic applications.
At one point OP-1 was viewed as Stryker’s possible competitor to Medtronic’s INFUSE bone graft, but it faced a number of setbacks. Stryker failed to get FDA approval after it was awarded a Humanitarian Device Exemption for the product, and legal issues surrounding its marketing cost that company millions and resulted in lawsuits, indictments, felony charges and even a U.S. Senate investigation.
In 2010, Stryker sold the OP-1 products to Olympus for US $60MM. But just four years later, Olympus halted commercialization efforts for OP-1, closing the plant it was manufactured in.
Later in 2014, Mariel Therapeutics acquired Stryker’s BMP-7 assets. Following this acquisition, Mariel merged with Ember Therapeutics, resulting in the combined company holding the exclusive, global license to the BMP-7 and OP-1 product lines.
The purchase of the OP-1 products by Viscogliosi Brothers comes less than one month after the private equity firm acquired Bioventus’ BMP development program. The Viscogliosi Brothers’ orthopaedic company portfolio also includes Paradigm Spine, Centinel Spine, Woven Orthopaedic Technologies, Aperion Biologics and FX Solutions.
Source: Ember Therapeutics
Ember Therapeutics entered into a letter of intent to divest its OP-1 bone morphogenetic protein (BMP-7) product family to Viscogliosi Brothers, LLC. The transaction is slated to close in late 3Q18 or 4Q18.
The OP-1 portfolio includes OP-1 Implant, OP-1 Putty, Opgenra and Osigraft for use in bone applications.
BMPs are members of the...
Ember Therapeutics entered into a letter of intent to divest its OP-1 bone morphogenetic protein (BMP-7) product family to Viscogliosi Brothers, LLC. The transaction is slated to close in late 3Q18 or 4Q18.
The OP-1 portfolio includes OP-1 Implant, OP-1 Putty, Opgenra and Osigraft for use in bone applications.
BMPs are members of the TGF-beta superfamily and guide mesenchymal stem cells to differentiate into osteoblasts to form bone in targeted tissues. Although 20 different recombinant human BMPs (rhBMPs) have been discovered, only rhBMP-2 is FDA approved and available for use in human spine surgery. BMP-7, marketed as OP-1, has potential use in treatment of osteoarthritis and other non-orthopaedic applications.
At one point OP-1 was viewed as Stryker’s possible competitor to Medtronic’s INFUSE bone graft, but it faced a number of setbacks. Stryker failed to get FDA approval after it was awarded a Humanitarian Device Exemption for the product, and legal issues surrounding its marketing cost that company millions and resulted in lawsuits, indictments, felony charges and even a U.S. Senate investigation.
In 2010, Stryker sold the OP-1 products to Olympus for US $60MM. But just four years later, Olympus halted commercialization efforts for OP-1, closing the plant it was manufactured in.
Later in 2014, Mariel Therapeutics acquired Stryker’s BMP-7 assets. Following this acquisition, Mariel merged with Ember Therapeutics, resulting in the combined company holding the exclusive, global license to the BMP-7 and OP-1 product lines.
The purchase of the OP-1 products by Viscogliosi Brothers comes less than one month after the private equity firm acquired Bioventus’ BMP development program. The Viscogliosi Brothers’ orthopaedic company portfolio also includes Paradigm Spine, Centinel Spine, Woven Orthopaedic Technologies, Aperion Biologics and FX Solutions.
Source: Ember Therapeutics
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
